全球細胞療法製造市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

全球細胞療法生產市場規模預計將從2025年的56億美元成長至2034年的190.1億美元，2026年至2034年的複合年成長率（CAGR）為14.54%。隨著細胞療法從研究階段邁向更廣泛的臨床開發和商業化階段，市場正迅速發展。對再生醫學、免疫療法和先進生物療法的投資不斷增加，催生了對專業生產能力的需求。細胞療法通常需要高度控制的流程，包括細胞收集、增殖、修飾、檢測、儲存和分發。隨著臨床研發管線的擴展，製藥和生技公司正在投資生產基礎設施，而專業的合約開發和生產機構（CDMO）也不斷提升自身能力。

技術創新正在推動可擴展性、自動化、品管和生產一致性的提升。封閉式系統處理、自動化細胞處理、先進生物反應器、數位化監控和改進的冷凍保存技術正在幫助應對生產挑戰。製造商也在開發標準化的工作流程，以減少變異性並提高效率。隨著個人化醫療的日益普及，對能夠處理患者特定材料的靈活生產系統的需求也日益成長。有關鑑別、純度、效力和可追溯性的監管要求也在推動對先進生產和品管基礎設施的投資。

未來前景與臨床成功、法規核准、生產規模化和成本降低密切相關。預計各公司將開發更多自動化和標準化的平台，以便在保持產品品質的同時服務更廣泛的患者群體。基因編輯和細胞工程技術的進步有望擴大需要特殊生產的療法範圍。此外，分散式和本地化生產模式的日益普及可能會改善療法的物流。隨著細胞療法研發管線的不斷發展，生產基礎設施預計將在更廣泛的先進療法生態系統中發揮日益重要的作用。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新的投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章 全球細胞療法製造市場：依療法類型分類

• 市場分析、洞察與預測
• 異體細胞療法
• 自體細胞療法

第5章 全球細胞療法製造市場：依技術類型分類

• 市場分析、洞察與預測
• 體細胞技術
• 細胞永生化技術
• 病毒載體技術
• 基因組編輯技術
• 細胞可塑性技術
• 3D技術

第6章：全球細胞療法製造市場：依製造目的分類

• 市場分析、洞察與預測
• 臨床階段
• 商業的
• 臨床前

第7章 全球細胞療法製造市場：依應用分類

• 市場分析、洞察與預測
• 肌肉骨骼系統
• 心血管系統
• 消化器官系統
• 神經系統
• 腫瘤學
• 皮膚科
• 其他

第8章 全球細胞療法製造市場：按地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 中國
  • 日本
  • 韓國
  • 印度
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第9章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第10章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Lonza Group Ltd
  • Thermo Fisher Scientific Inc
  • Cytiva
  • Sartorius AG
  • WuXi AppTec Co.Ltd
  • Charles River Laboratories InternationalInc
  • CatalentInc
  • Samsung Biologics Co.Ltd
  • Fujifilm Diosynth Biotechnologies
  • AGC Biologics
  • Boehringer Ingelheim
  • KBI BiopharmaInc
  • Minaris Regenerative Medicine
  • Novartis AG
  • Miltenyi Biotec BV & Co. KG
  • MaxCyteInc
  • OriGen Biomedical
  • BioNTech SE
  • AstraZeneca PLC
  • Takara Bio Inc

The global cell therapy manufacturing market size is expected to reach USD 19.01 Billion in 2034 from USD 5.60 Billion in 2025, growing at a CAGR of 14.54% during 2026-2034.This market is developing rapidly as cell-based therapies progress from research programs toward broader clinical development and commercialization. Increasing investment in regenerative medicine, immunotherapy, and advanced biological treatments is creating demand for specialized manufacturing capabilities. Cell therapies often require highly controlled processes involving cell collection, expansion, modification, testing, storage, and distribution. Growing clinical pipelines are encouraging pharmaceutical companies and biotechnology firms to invest in manufacturing infrastructure, while specialized contract development and manufacturing organizations are expanding their capabilities.

Technological innovation is supporting improvements in scalability, automation, quality control, and manufacturing consistency. Closed-system processing, automated cell handling, advanced bioreactors, digital monitoring, and improved cryopreservation technologies are helping address production challenges. Manufacturers are also developing standardized workflows to reduce variability and improve efficiency. Increasing adoption of personalized therapies is creating demand for flexible manufacturing systems capable of processing patient-specific materials. Regulatory requirements surrounding identity, purity, potency, and traceability are also encouraging investment in advanced manufacturing and quality-management infrastructure.

Future prospects are closely linked to clinical success, regulatory approvals, manufacturing scalability, and cost reduction. Companies are expected to develop more automated and standardized platforms capable of supporting larger patient populations while maintaining product quality. Advances in gene editing and cell engineering could expand the range of therapies requiring specialized manufacturing. Greater use of decentralized and regional production models may also improve treatment logistics. As the pipeline of cell-based therapies continues developing, manufacturing infrastructure is expected to become increasingly important to the broader advanced-therapy ecosystem.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Therapy Type

• Allogeneic Cell Therapy
• Autologous Cell Therapy

By Technology Type

• Somatic Cell Technology
• Cell Immortalization Technology
• Viral Vector Technology
• Genome Editing Technology
• Cell Plasticity Technology
• 3D Technology

By Manufacturing Purpose

• Clinical
• Commercial
• Pre-clinical

By Application

• Musculoskeletal
• Cardiovascular
• Gastrointestinal
• Neurological
• Oncology
• Dermatology
• Others

COMPANIES PROFILED

• Lonza Group Ltd., Thermo Fisher Scientific Inc., Cytiva, Sartorius AG, WuXi AppTec Co., Ltd., Charles River Laboratories International, Inc., Catalent, Inc., Samsung Biologics Co., Ltd., Fujifilm Diosynth Biotechnologies, AGC Biologics, Boehringer Ingelheim, KBI Biopharma, Inc., Minaris Regenerative Medicine, Novartis AG, Miltenyi Biotec B.V. & Co. KG, MaxCyte, Inc., OriGen Biomedical, BioNTech SE, AstraZeneca PLC, Takara Bio Inc.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY THERAPY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Therapy Type
• 4.2. Allogeneic Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Autologous Cell Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY TECHNOLOGY TYPE 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Technology Type
• 5.2. Somatic Cell Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Cell Immortalization Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Viral Vector Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Genome Editing Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Cell Plasticity Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. 3D Technology Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY MANUFACTURING PURPOSE 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Manufacturing Purpose
• 6.2. Clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Commercial Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Pre-clinical Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY APPLICATION 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Application
• 7.2. Musculoskeletal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Cardiovascular Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Gastrointestinal Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.5. Neurological Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.6. Oncology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.7. Dermatology Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.8. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL CELL THERAPY MANUFACTURING MARKET: BY REGION 2022-2034 (USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Therapy Type
  • 8.2.2 By Technology Type
  • 8.2.3 By Manufacturing Purpose
  • 8.2.4 By Application
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Therapy Type
  • 8.3.2 By Technology Type
  • 8.3.3 By Manufacturing Purpose
  • 8.3.4 By Application
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Spain
  • 8.3.10 Russia
  • 8.3.11 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Therapy Type
  • 8.4.2 By Technology Type
  • 8.4.3 By Manufacturing Purpose
  • 8.4.4 By Application
  • 8.4.5 China
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 India
  • 8.4.9 Australia
  • 8.4.10 South East Asia
  • 8.4.11 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Therapy Type
  • 8.5.2 By Technology Type
  • 8.5.3 By Manufacturing Purpose
  • 8.5.4 By Application
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Therapy Type
  • 8.6.2 By Technology Type
  • 8.6.3 By Manufacturing Purpose
  • 8.6.4 By Application
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL CELL THERAPY MANUFACTURING INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 Lonza Group Ltd
  • 10.2.2 Thermo Fisher Scientific Inc
  • 10.2.3 Cytiva
  • 10.2.4 Sartorius AG
  • 10.2.5 WuXi AppTec Co.Ltd
  • 10.2.6 Charles River Laboratories InternationalInc
  • 10.2.7 CatalentInc
  • 10.2.8 Samsung Biologics Co.Ltd
  • 10.2.9 Fujifilm Diosynth Biotechnologies
  • 10.2.10 AGC Biologics
  • 10.2.11 Boehringer Ingelheim
  • 10.2.12 KBI BiopharmaInc
  • 10.2.13 Minaris Regenerative Medicine
  • 10.2.14 Novartis AG
  • 10.2.15 Miltenyi Biotec B.V. & Co. KG
  • 10.2.16 MaxCyteInc
  • 10.2.17 OriGen Biomedical
  • 10.2.18 BioNTech SE
  • 10.2.19 AstraZeneca PLC
  • 10.2.20 Takara Bio Inc